Consortium for Immunotherapeutics against Emerging Viral Threats

  • Funded by National Institutes of Health (NIH)
  • Total publications:0 publications

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2020
    2022
  • Known Financial Commitments (USD)

    $2,688,763
  • Funder

    National Institutes of Health (NIH)
  • Principle Investigator

    Pending
  • Research Location

    United States of America, Americas
  • Lead Research Institution

    LA JOLLA INSTITUTE FOR IMMUNOLOGY
  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Pathogen genomics, mutations and adaptations

  • Special Interest Tags

    Gender

  • Study Subject

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

ABSTRACT We recently galvanized the Coronavirus Immunotherapeutic Consortium, CoVIC, an international effortto conduct side-by-side analyses of leading therapeutic antibody candidates against the SARS-CoV-2 Spikeprotein contributed by a range of large and small companies and academic labs on multiple continents. CoVICprovides an opportunity for side-by-side analysis of the leading therapeutic candidates under the same assayconditions, as well as real-time collaborative assembly of a broader, deeper dataset on the activities andpotencies of antibodies against SARS-CoV-2 than could be assembled by any single discovery effort alone. Thecurrently funded CoVIC studies focus largely on characteristics of the Fab region of the IgG therapeutic: bindingand mechanical neutralization, and analyze only spike from the original Wuhan reference strain of SARS-CoV-2. The proposed supplement will provide support for critical components that are currently missing from CoVICbut which are needed to accelerate clinical advancement of antibodies that will be safe, efficacious and offerdurable protection. We will determine Fc-mediated activities of the therapeutic antibodies, the likelihood or riskof enhancement from clinical candidates, and which epitopes and sites of and susceptibility to mutagenic escape.The resulting body of information will inform early and next-generation antibody therapies and will ensure thattherapeutics are known which are responsive to emerging viral variants.